Dana-farber Cancer Institute

This study tested whether a combination of two immunotherapy drugs, durvalumab and tremelimumab, could help control advanced malignant pleural mesothelioma. It was for people whose cancer had progressed after standard chemotherapy. The goal was to see if boosting the body's immun…

This study tested whether adding an immunotherapy drug called avelumab to standard bladder radiation could help treat muscle-invasive bladder cancer. It was for patients who could not receive the usual first-choice chemotherapy. The goal was to see if this combination could bette…

This study tested an experimental drug called BVD-523 in people with advanced uveal melanoma, a rare cancer that starts in the eye. The goal was to see if the drug could shrink tumors by blocking a specific protein that helps the cancer grow. The trial was small and ended early, …

This study tested whether adding a hormone-blocking drug (fulvestrant) to a targeted cancer drug (neratinib) worked better than the targeted drug alone for advanced breast cancer that had spread. It involved 21 women with specific types of breast cancer (HER2-positive and ER-posi…

This study tested whether the drug abemaciclib could help control advanced triple-negative breast cancer that had spread to other parts of the body. Researchers enrolled 27 patients whose cancer tested positive for a specific protein called Rb. The trial was terminated early, and…

This study tested whether adding an experimental drug called GDC-0084 to the standard treatment Herceptin could help control breast cancer that had spread to the brain. It involved 17 people with a specific type of breast cancer (HER2-positive) that had formed new or growing tumo…

This study aimed to find biological markers in the blood or tumor that could predict how well patients with advanced non-small cell lung cancer respond to a combination of two immunotherapy drugs (ipilimumab and nivolumab). It was a small, early-phase trial that enrolled only 5 p…